| Product Name | CTXI ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Synonyms | CTX-I; CTX1; |
| Method | Competitive |
| Detection Range | 123.5-10,000pg/mL |
| Sensitivity | 50.5pg/mL |
| Target | CTXI |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI). No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 50uL standard or sample to each well. And then add 50uL prepared Detection Reagent A immediately. Shake and mix.Incubate 1 hour at 37℃; 3.Aspirate and wash 3 times; 4.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 5.Aspirate and wash 5 times; 6.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 7.Add 50uL Stop Solution.Read at 450 nm immediately. |
| Uniprot | Q9NPZ5 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Is there benefit in optimising heart failure treatment in over-80 year-old patients? (HF-80 study): study protocol for a randomized controlled trial.;A Mediterranean Diet Enriched with Olive Oil Is Associated with Higher Serum Total Osteocalcin Levels in Elderly Men at High Cardiovascular Risk;Oxytocin Reverses Ovariectomy-Induced Osteopenia and Body Fat Gain;Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease;Bone resorption correlates with the frequency of CD5+ B cells in the blood of patients with rheumatoid arthritis;The presence of FCGR2B promoter or transmembrane region variant alleles leads to reduced serum IL-6 levels in rheumatoid arthritis;Osteocartilaginous metabolic markers change over a 3-week stage race in pro-cyclists;Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients;Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis;High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients.;The effect of calcium and vitamin D supplementation on bone health of male Jockeys.;A potential role for glycated cross-links in abdominal aortic aneurysm disease.;Obesity status influences the relationship among serum osteocalcin, iron stores and insulin sensitivity;PINP β-CTX 2 .;Geometric and mechanical bone response to a multidisciplinary weight loss intervention in adolescents with obesity: The ADIBOX study;Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis;Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors;Biomarkers of oral inflammation in perinatally HIV‐infected and perinatally HIV exposed, uninfected youth;AAV-anti-miR-214 prevents collapse of the femoral head in osteonecrosis by regulating osteoblast and osteoclast activities;Differences in Osteoimmunological Biomarkers Predictive of Psoriatic Arthritis among a Large Italian Cohort of Psoriatic Patients;Article Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous …;Postmenapozal Tip-2 diyabetes mellitus' lu hastalarda osteoporoza bağlı kırık riskinin ve kemik Turnoveri'nin değerlendirilmesi;Night shift work and osteoporosis-bone turnover markers among female blue-collar workers in Poland; |
| Supplier | Cloud Clone |
PROTOCOLS:
CEA665Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
